• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sol-Gel Technologies Ltd. (Amendment)

    2/12/24 12:46:44 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLGL alert in real time by email
    SC 13G/A 1 zk2430929.htm SC 13G/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549

    SCHEDULE 13G
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 7)*

    Sol-Gel Technologies Ltd.
    (Name of Issuer)

    Ordinary Shares, par value NIS 0.1 per share
     (Title of Class of Securities)

    M8694L103
     (CUSIP Number)

    December 31, 2023
     (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


    CUSIP No. M8694L103
    13G
    Page 2 of 8 Pages
     
    1
    NAMES OF REPORTING PERSONS
     
     
     
    The Phoenix Holdings Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)
       
    (a) ☐
       
    (b) ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Israel
     
     
     
     
    NUMBER OF
    SHARES BENEFICIALLY OWNED BY
    EACH REPORTING PERSON
    WITH
    5
    SOLE VOTING POWER
     
     
     
    ---
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     
    2,574,922  (*)
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    ---
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    2,574,922  (*)
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    2,574,922  (*)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
    9.26% (*)(**)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (See instructions)
     
     
     
    CO
     
     
     
     
     
    (*) The beneficial ownership of the securities reported herein is described in Item 4(a).

    (**) Based on 27,805,954 Ordinary Shares outstanding as of January 9, 2024 (as reported on Bloomberg LP).

    2

    Item 1.        (a)         Name of Issuer:

             Sol-Gel Technologies Ltd.

                         (b)
    Address of Issuer's Principal Executive Offices:

     7 Golda Meir St., Ness Ziona 7403650, Israel

    Item 2.        (a)
    Name of Person Filing:

    The Phoenix Holdings Ltd.

    The securities reported herein are beneficially owned by various direct or indirect, majority or wholly-owned subsidiaries of the Phoenix Holdings Ltd. (the "Subsidiaries").  The Subsidiaries manage their own funds and/or the funds of others, including for holders of exchange-traded notes or various insurance policies, members of pension or provident funds, unit holders of mutual funds, and portfolio management clients. Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions.


    (b)
    Address of Principal Business Office:

      The address of the Phoenix Holdings Ltd. is Derech Hashalom 53, Givataim, 53454, Israel.


    (c)
    Citizenship:

    The Phoenix Holdings Ltd. - Israel


    (d)
    Title of Class of Securities:

    Ordinary Shares, par value NIS 0.1 per share


    (e)
    CUSIP Number:

    M8694L103

    Item 3.
    Not applicable.

    Item 4.
    Ownership:


    (a)
    Amount beneficially owned:

    See row 9 of cover page of each reporting person.

    Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions.  Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by either the Filing Persons or Subsidiaries that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each reporting person disclaims the existence of any such group.  In addition, each of the Filing Persons and Subsidiaries disclaims any beneficial ownership of the securities covered by this report in excess of their actual pecuniary interest therein. This Statement shall not be construed as an admission by the Filing Persons or Subsidiaries that they are the beneficial owners of any of the Ordinary Shares covered by this Statement, and each of Filing Persons and Subsidiaries disclaims beneficial ownership of any such Ordinary Shares.
    3


    As of December 31, 2023, the securities reported herein were held as follows:

       
    Ordinary Shares
       
    Percentage of total Ordinary Shares outstanding
     
    The Phoenix Investments House - "nostro" accounts
       
    --
         
    --
     
    The Phoenix Investments House - trust funds
       
    --
         
    --
     
    The Phoenix Investments House - ETF's
       
    --
         
    --
     
    The Phoenix "nostro" accounts
       
    288,045
         
    1.04
    %
    The Phoenix pension
       
    --
         
    --
     
    The Phoenix pension and provident funds
       
    --
         
    --
     
    Partnership for Israeli shares (1)
       
    --
         
    --
     
    Partnership for investing in shares indexes (1)
       
    --
         
    --
     
    Partnership for international shares (1)
       
    2,286,877
         
    8.22
    %
    Halman - Aldubi Provident and Pension Funds Ltd.
       
    --
         
    --
     

    (1) All ownership rights in this partnership belong to companies that are part of Phoenix Group. The amount of ownership rights held by such companies in the partnership changes frequently according to a mechanism provided in the partnership agreement.


    (b)
    Percent of class:

    See row 11 of cover page of each reporting person


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote:

    See row 5 of cover page of each reporting person


    (ii)
    Shared power to vote or to direct the vote:

    See row 6 of cover page of each reporting person and note in Item 4(a) above


    (iii)
    Sole power to dispose or to direct the disposition of:

    See row 7 of cover page of each reporting person


    (iv)
    Shared power to dispose or to direct the disposition of:

    See row 8 of cover page of each reporting person and note in Item 4(a) above

    4




    Item 5.
    Ownership of Five Percent or Less of a Class:

    Not applicable.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another:

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group:

    Not applicable.

    Item 9.
    Notice of Dissolution of Group:

    Not applicable.

    5

     
    Item 10.
    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    6


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    February 12, 2024
     
         
    The Phoenix Holdings Ltd.
     
    /s/ Eli Schwartz
    By: Eli Schwartz*
    Title: Executive Vice President - Chief Financial Officer

         
    /s/ Haggai Schreiber
    By: Haggai Schreiber*
    Title: Executive Vice President - Chief Investment Officer
     

    * Signature duly authorized by resolution of the Board of Directors, notice of which is attached as Exhibit 1 to this Schedule 13G.
    7

     
    EXHIBIT NO.          DESCRIPTION
     
    Exhibit 1
    Notice of resolution of the Board of Directors of the Phoenix Holdings Ltd., dated as of December 12, 2019 (incorporated herein by reference to Exhibit 1 to the Schedule 13G filed on February 7, 2022).

     8

     
    Get the next $SLGL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLGL

    DatePrice TargetRatingAnalyst
    8/19/2024$6.00 → $4.00Strong Buy → Outperform
    Raymond James
    10/21/2022$5.50Hold
    Jefferies
    11/15/2021$21.00 → $20.00Buy
    HC Wainwright & Co.
    11/12/2021$23.00 → $21.00Strong Buy
    Raymond James
    7/28/2021$20.00 → $21.00Buy
    HC Wainwright & Co.
    7/12/2021$21.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SLGL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TWYNEO issued to SOL-GEL TECHNOLOGIES LTD

    Submission status for SOL-GEL TECHNOLOGIES LTD's drug TWYNEO (ORIG-1) with active ingredient TRETINOIN;BENZOYL PEROXIDE has changed to 'Approval' on 07/26/2021. Application Category: NDA, Application Number: 214902, Application Classification: Type 4 - New Combination

    7/27/21 10:39:03 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sol-Gel downgraded by Raymond James with a new price target

    Raymond James downgraded Sol-Gel from Strong Buy to Outperform and set a new price target of $4.00 from $6.00 previously

    8/19/24 6:57:49 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Sol-Gel with a new price target

    Jefferies resumed coverage of Sol-Gel with a rating of Hold and set a new price target of $5.50

    10/21/22 7:42:15 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Sol-Gel Technologies with a new price target

    HC Wainwright & Co. reiterated coverage of Sol-Gel Technologies with a rating of Buy and set a new price target of $20.00 from $21.00 previously

    11/15/21 1:18:47 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    Leadership Updates

    Live Leadership Updates

    View All

    Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

    Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the third quarter ended September

    11/15/24 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribersSol-Gel's cash runway expected to extend through the end of the first quarter of 2024 NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the third quarter ended September 30, 2022 and provided a corporate update. Alon Seri-Levy, PhD, Chief Executive Officer of Sol-Gel, stated, "We are very pleased with the continu

    11/10/22 4:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

    NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today the appointment of Michael Glezin to the position of Vice President, Business Development. In this position, Mr. Glezin will be responsible for identifying new in-licensing business opportunities as well as potential commercial partners for the Company's approved products in ex-US territories. "We are very pleased to have Michael join the Company as we expand our business development efforts," stated Alon Seri-Levy,

    10/3/22 8:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    Financials

    Live finance-specific insights

    View All

    Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

    An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of SGT-610 (Patidegib gel, 2%), an Orphan Drug candidate with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome and partnered with Galderma to commercialize two approved lar

    3/13/24 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

    Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Phase 1 trial for SGT-210 (erlotinib) demonstrated no systemic absorption-related adverse events; Sol-Gel intends to advance this drug candidate Sol-Gel has cash runway into the second half of 2025 NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with two innovative dermatology products, EPSOLAY and TWYNEO, that were launched in the U.S., SGT-610, which is Phase 3

    5/12/23 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

    Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel's pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndromeA Phase 3 study of SGT-610 is expected to initiate in the second half of 2023, with results expected by the end of 2025The base of recurrent TWYNEO® prescribers was 82% in Q4 2022, while the EPSOLAY® recurrent prescriber base has grown to 64% during the same periodFollowing recent financing, Sol-Gel's cash runway expected to extend into the second half of 2025 NESS ZIONA, Israel, March 10, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company wi

    3/10/23 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sol-Gel Announces Health Canada Approval of EPSOLAY®

    NESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, a Phase-1b, double blinded clinical trial of SGT-210 (erlotinib ointment, 5%) on Darier disease patients and with two approved large-category dermatology products, TWYNEO and EPSOLAY, announced today that on August 27, 2025 Health Canada issued a Notice of Compliance (NOC) for EPSOLAY for the treatment of inflammatory lesions of rosacea in adults. This approval comes as a result of Sol-Gel's partnership with Searchlig

    9/4/25 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

    Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expected in the fourth quarter of 2026Phase-1b proof-of-concept clinical trial of SGT-210 for Darier disease is ongoingSol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S. for a total consideration of $16 million to be received during 2025Following recent transactions, Sol-Gel's cash runway is expected to extend into the first quarter of 2027 NESS ZIONA, Israel, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting

    8/15/25 7:00:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sol-Gel Reports First Quarter 2025 Results

    NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the First Quarter Year Ended March 31st, 2025 Total revenue in the first quarter was $1 million compared to $0.5 million revenues for the same period in 2024. Research and development expenses were $8.8 million compared to $5.3 million in the same period in 2024. The increase of $3.5 million was primarily attributed to an increase of $3.6 million due to expenses associated with supplier-led ma

    5/23/25 7:15:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    SEC Filings

    View All

    SEC Form 6-K filed by Sol-Gel Technologies Ltd.

    6-K - Sol-Gel Technologies Ltd. (0001684693) (Filer)

    9/4/25 7:00:10 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Sol-Gel Technologies Ltd.

    SCHEDULE 13G - Sol-Gel Technologies Ltd. (0001684693) (Subject)

    8/29/25 4:05:24 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Sol-Gel Technologies Ltd.

    EFFECT - Sol-Gel Technologies Ltd. (0001684693) (Filer)

    8/19/25 12:15:02 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sol-Gel Technologies Ltd.

    SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

    11/14/24 4:37:49 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sol-Gel Technologies Ltd.

    SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

    11/14/24 6:17:23 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Sol-Gel Technologies Ltd. (Amendment)

    SC 13D/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

    4/8/24 9:28:09 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care